Systemic, Vascular Diseases and Ageing

Summary

The Systemic, Vascular Diseases and Ageing group studies the impact and treatment of systemic diseases (i.e. diseases affecting more than one organ) from the clinical and epidemiological perspective to the lab setting. Its area of experience includes the fields of systemic autoimmune diseases, venous thromboembolic disease, ageing (mainly chronic heart failure) and hemorrhagic hereditary telangiectasia and other vascular rare diseases. Regarding rare diseases, this group also studies these diseases from the basic research, with cellular and animal models. In fact, we practice a real translational research, transfering the insights from a laboratory environment into a clinical one, avoiding any gap in the transition between both settings.

1452

Publications

Strategic lines

Autoimmune, autoinflammatory and systemic diseases
Chronicity and aging
Venous thromboembolic disease
Hereditary hemorrhagic telangiectasia and other vascular rare diseases
Minority vascular and storage diseases
Adult immunopathies
Allergology
Cardiovascular risk factors and atherosclerosis
Complex dyslipidemias
Angiogenesis and blood vessel remodeling
Leukocyte extravasation and inflammation

Selected Publications

Arribas V, Onetti Y, Ramiro-Pareta M, Villacampa P, Beck H, Alberola M, Esteve-Codina A, Merkel A, Sperandio M, Martínez-Estrada OM, Schmid B, Montanez E. Endothelial TDP-43 controls sprouting angiogenesis and vascular barrier integrity, and its deletion triggers neuroinflammation. JCI Insight. 2024 Feb 1:e177819. doi: 10.1172/jci.insight.177819. Epub ahead of print. PMID: 38300714.

Candás-Estébanez B, Fernández-Cidón B, Corbella E, Tebé C, Fanlo-Maresma M, Esteve-Luque V, Salas-Salvadó J, Fitó M, Riera-Mestre A, Ros E, Pintó X. The Impact of the Mediterranean Diet and Lifestyle Intervention on Lipoprotein Subclass Profiles among Metabolic Syndrome Patients: Findings of a Randomized Controlled Trial. Int J Mol Sci. 2024 Jan 22;25(2):1338. doi: 10.3390/ijms25021338. PMID: 38279337; PMCID: PMC10817060.

Genet G, Genet N, Paila U, Cain SR, Cwiek A, Chavkin NW, Serbulea V, Figueras A, Cerdà P, McDonnell SP, Sankaranarayanan D, Huba M, Nelson EA, Riera-Mestre A, Hirschi KK. Induced Endothelial Cell CycleArrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia. Circulation. 2023 Dec 21. doi: 10.1161/CIRCULATIONAHA.122.062952. Epub ahead of print. PMID: 38126211.

Bastard P, Vazquez S, Liu J, Laurie MT, Wang CY, Gervais A, Le Voyer T, Bizien L, Zamecnik C, Philippot Q, Rosain J, Catherinot E, Willmore A, Mitchell AM, Bair R, Garçon P, Kenney H, Fekkar A, Salagianni M, Poulakou G, Siouti E, Sahanic S, Tancevski I, Weiss G, Nagl L, Manry J, Duvlis S, Arroyo Sánchez D, Paz Artal E, Rubio L, Perani C, Bezzi M, Sottini A, Quaresima V, Roussel L, Vinh DC, Reyes LF, Garzaro M, Hatipoglu N, Boutboul D, Tandjaoui Lambiotte Y, Borghesi A, Aliberti A, Cassaniti I, Venet F, Monneret G, Halwani R, Sharif Askari NS, Danielson J, Burrel S, Morbieu C, Stepanovskyy Y, Bondarenko A, Volokha A, Boyarchuk O, Gagro A, Neuville M, Neven B, Hernu R, Bal A, Novelli A, Novelli G, Saker K, Ailioaie O, Antolí A, Jeziorski E, Rocamora Blanch G, Teixeira C, Delaunay C, Lhuillier M, Le Turnier P, Zhang Y, Mahevas M, Pan Hammarström Q, Abolhassani H, Bompoil T, Dorgham K, COVID HGE consortium †, French COVID study group †, COMET consortium †, Gorochov G, Laouenan C, Rodríguez Gallego C, NGLFP, Renia L, Pujol A, Belot A, Raffi F, Allende LM, Martinez Picado J, Ozcelik T, Keles S, Imberti L, Notarangelo LD, Troya J, Solanich X, Zhang SY, Puel A, Wilson MR, Trouillet Assant S, Abel L, Jouanguy E, Ye CJ, Cobat A, Thompson LM, Andreakos E, Zhang Q, Anderson MS, Casanova JL, DeRisi JL. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci. Immunol. 2022;doi:10.1126/sciimmunol.abp8966.

Corsonello A, Soraci L, Ärnlöv J, Carlsson AC, Roller Wirnsberger R, Wirnsberger G, Mattace Raso F, Tap L, Formiga F, Moreno González R, Kostka T, Guligowska A, Artzi Medvedik R, Melzer I, Weingart C, Sieber C, Lattanzio F, Screening for among Older People across Europe (SCOPE) study investigators CKD. The relevance of geriatric assessments on the association between chronic kidney disease stages and mortality among older people: a secondary analysis of a multicentre cohort study. Age Ageing. 2022;51(7):doi:10.1093/ageing/afac168.

Selected Projects

PI23/00651. Papel de los autoanticuerpos que neutralizan interferones de tipo I en el lupus eritematoso sistémico. AES2023. Budget: 202.500,00 €. 2024-2026. PI: Solanich Moreno, Xavier

PID2022-141840OB-I00. Deciphering the role of TDP-43 in angiogenesis, vascular barrier and homostasis of blood vessels under both physiological and pathological conditions. (NeuVasTDP43). Budget: 200.000€. 2023-2026. PI: Montañez Miralles, Eloi.

CNS2023-144390. Caracterización de un nuevo modelo animal de fibrosis retinal mediada por pericitos. Consolidación Investigadora 2023 (MCINN). Budget: 199.890,34 € 2023-2025. PI: Villacampa Alcubierre, Pilar.
PI23/00164. Nuevo conocimiento en el desarrollo de malformaciones vasculares hepáticas en los pacientes con Telangiectasia Hemorrágica Hereditaria . Proyectos de investigación en Salud (AES 2023). Budget: 167.500€. 2024-2027. PI: Riera Mestre, Antoni.

2023-713-1. Desxifrar el paper de TDP-43 en la barrera vascular i l'estabilitat dels vasos sanguinis. La Marató TV3 2022. Budget: 120.000€. PI: Montañez Miralles, Eloi.

2022-109-1. ESTUDIO DE EXTENSIÓN ABIERTO DE FASE 3 PARA EVALUAR LA EFICACIA Y LA SEGURIDAD A LARGO PLAZO DE LIB003 EN PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HOMOCIGÓTICA Y HETEROCIGÓTICA, ENFERMEDAD CARDIOVASCULAR O ALTO RIESGO DE ENFERMEDAD CARDIOVASCULAR, EN TRATAMIENTO HIPOLIPEMIANTE ESTABLE QUE PRECISAN UNA REDUCCIÓN ADICIONAL DEL COLESTEROL UNIDO A LAS LIPOPROTEÍNAS DE BAJA DENSIDAD (LIBerate-OLE). Medpace. Budget: 401.128€. 2022- . PI: Pintó Sala, Xavier.

2022-179-1. ESTUDIO DEMOSTRATIVO PRELIMINAR, ALEATORIZADO, CONTROLADO CON PLACEBO, CON DOBLE ENMASCARAMIENTO, MULTICÉNTRICO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE DOS DOSIS DE VAD044 EN PACIENTES CON TELANGIECTASIA HEMORRÁGICA HEREDITARIA (THH). ORION CLINICAL SERVICES LTD. Budget: 255.000€. 2022- . PI: Riera Mestre, Antoni.

FIS21148. CONTRATOS PREDOCTORALES DE FORMACION EN INVESTIGACION EN SALUD (PFIS). Instituto de Salud Carlos III (ISCIII). Budget: 119.567€. 2022-2025. PI: Riera Mestre, Antoni.